Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERN1 | O75460 | 2/20 | 0.57 |
| ▸ | ACMSD | Q8TDX5 | 1/20 | 0.57 |
| ▸ | HSD17B1 | P14061 | 5/20 | 0.50 |
| ▸ | HSD17B2 | P37059 | 5/20 | 0.50 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.49 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.46 |
| ▸ | CYP2A6 | P11509 | 3/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.42 |
| ▸ | CYP2E1 | P05181 | 1/20 | 0.42 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.42 |
| ▸ | ESR1 | P03372 | 1/20 | 0.41 |
| ▸ | PTPRC | P08575 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14506751 | 0.82 | KCNH2 (0.53) | ERN1ACMSDKCNH2CYP2A6CYP2E1 | |
| SCHEMBL29429121 | 0.81 | HSD17B1 (0.68) | HSD17B1HSD17B2ESR2CYP3A4CYP2D6 | |
| SCHEMBL29696046 | 0.81 | HSD17B1 (0.68) | HSD17B1HSD17B2ESR2CYP3A4CYP2D6 | |
| SCHEMBL272034 | 0.81 | HSD17B1 (0.68) | HSD17B1HSD17B2ESR2CYP3A4CYP2D6 | |
| SCHEMBL26979937 | 0.81 | HSD17B1 (0.68) | HSD17B1HSD17B2ESR2CYP3A4CYP2D6 | |
| SCHEMBL13589555 | 0.79 | HSD17B1 (0.72) | HSD17B1HSD17B2ESR2CYP3A4CYP2D6 | |
| Hydrogen Sulfide SCHEMBL6269773 | 0.79 | HSD17B1 (0.65) | HSD17B1HSD17B2ESR2CYP3A4CYP2D6 | |
| Hydrogen Sulfide SCHEMBL22042810 | 0.79 | HSD17B1 (0.65) | HSD17B1HSD17B2ESR2CYP3A4CYP2D6 | |
| SCHEMBL3811825 | 0.79 | HSD17B1 (0.72) | HSD17B1HSD17B2ESR2CYP3A4CYP2D6 | |
| SCHEMBL18717328 | 0.77 | KCNH2 (0.69) | ERN1ACMSDKCNH2CYP3A4CYP2A6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020018747-A1 | METHOD OF MODULATING RIBONUCLEOTIDE REDUCTASE | CASE WESTERN RESERVE UNIVERSITY (US) | 2020-01-23 | — | — | WO | disclosed |
| US-8263657-B2 | Blocking neurokinins; using a benzene compound containing hydroxy or acetoxy group; antiinflammatory agents | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2012-09-11 | — | — | US | disclosed |
| US-8263657-B2 | Blocking neurokinins; using a benzene compound containing hydroxy or acetoxy group; antiinflammatory agents | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2012-09-11 | — | — | US | disclosed |
| EP-1352650-B1 | INHIBITORS AGAINST THE PRODUCTION AND RELEASE OF INFLAMMATORY CYTOKINES | INST MED MOLECULAR DESIGN INC (JP) | 2012-03-07 | — | — | EP | disclosed |
| US-8097759-B2 | Inflammatory cytokine release inhibitor | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2012-01-17 | — | — | US | disclosed |
| US-8097759-B2 | Inflammatory cytokine release inhibitor | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2012-01-17 | — | — | US | disclosed |
| US-20100274051-A1 | INFLAMMATORY CYTOKINE RELEASE INHIBITOR | INSTITUTE OF MEDICINAL MOLECULAR DESIGN. INC. (JP) | 2010-10-28 | — | — | US | disclosed |
| US-20100274051-A1 | INFLAMMATORY CYTOKINE RELEASE INHIBITOR | INSTITUTE OF MEDICINAL MOLECULAR DESIGN. INC. (JP) | 2010-10-28 | — | — | US | disclosed |
| US-20090192122-A2 | INFLAMMATORY CYTOKINE RELEASE INHIBITOR | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2009-07-30 | — | — | US | disclosed |
| US-20090192122-A2 | INFLAMMATORY CYTOKINE RELEASE INHIBITOR | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2009-07-30 | — | — | US | disclosed |
| EP-1847263-A2 | Inhibitors against the production and release of inflammatory cytokines | Institute of Medicinal Molecular Design, Inc. (JP) | 2007-10-24 | — | — | EP | disclosed |
| EP-1844766-A2 | Inhibitors against the production and release of inflammatory cytokines | Institute of Medicinal Molecular Design, Inc. (JP) | 2007-10-17 | — | — | EP | disclosed |
| US-20070185059-A1 | Antiallergic agents | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2007-08-09 | — | — | US | disclosed |
| US-20070185059-A1 | Antiallergic agents | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2007-08-09 | — | — | US | disclosed |
| US-20070185110-A1 | Antiallergic agents | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2007-08-09 | — | — | US | disclosed |
| US-20070185110-A1 | Antiallergic agents | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2007-08-09 | — | — | US | disclosed |
| CN-1326519-C | Compounds and uses thereof for decreasing activity of hormone-sensitive lipase | NOVO NORDISK AS (DK) | 2007-07-18 | — | — | CN | disclosed |
| US-20070042997-A1 | Medicament for treatment of dermal pigmentation | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2007-02-22 | — | — | US | disclosed |
| US-20070042997-A1 | Medicament for treatment of dermal pigmentation | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2007-02-22 | — | — | US | disclosed |
| CN-1602191-A | Compounds and uses thereof for decreasing activity of hormone-sensitive lipase | NOVO NORDISK AS (DK) | 2005-03-30 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100274051-A1 | INFLAMMATORY CYTOKINE RELEASE INHIBITOR | IL1B, NFKBIA, IL1A | ERN1 1883/4885ACMSD 2037/4885HSD17B1 220/4885 |
| US-20090192122-A2 | INFLAMMATORY CYTOKINE RELEASE INHIBITOR | IL1B, NFKBIA, IL1A | ERN1 1918/4885ACMSD 1968/4885HSD17B1 261/4885 |
| US-20070185110-A1 | Antiallergic agents | NAT1, EPX, AHR | ERN1 2842/4885ACMSD 92/4885HSD17B1 275/4885 |
| US-20070185059-A1 | Antiallergic agents | NAT1, EPX, AHR | ERN1 2799/4885ACMSD 96/4885HSD17B1 233/4885 |
| US-20070042997-A1 | Medicament for treatment of dermal pigmentation | TYR, XDH, XPA | ERN1 4490/4885ACMSD 1166/4885HSD17B1 714/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.